Two Seas Capital LP bought a new stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 14,835,146 shares of the biotechnology company's stock, valued at approximately $7,992,000. Adaptimmune Therapeutics accounts for 0.6% of Two Seas Capital LP's investment portfolio, making the stock its 19th biggest holding. Two Seas Capital LP owned approximately 5.80% of Adaptimmune Therapeutics as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of ADAP. Two Sigma Investments LP increased its position in shares of Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after buying an additional 21,688 shares in the last quarter. Invesco Ltd. boosted its position in Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Adaptimmune Therapeutics by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Trading Up 2.1%
NASDAQ ADAP traded up $0.01 during trading hours on Monday, reaching $0.28. The company had a trading volume of 386,431 shares, compared to its average volume of 1,827,862. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $73.25 million, a P/E ratio of -1.27 and a beta of 2.86. The stock has a 50-day moving average of $0.27 and a 200 day moving average of $0.48. Adaptimmune Therapeutics plc has a 1-year low of $0.20 and a 1-year high of $1.48.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $7.29 million for the quarter, compared to the consensus estimate of $6.55 million. As a group, research analysts anticipate that Adaptimmune Therapeutics plc will post -0.14 earnings per share for the current fiscal year.
Analyst Ratings Changes
ADAP has been the subject of a number of analyst reports. Barclays dropped their price target on Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research report on Wednesday, May 14th. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Wall Street Zen assumed coverage on shares of Adaptimmune Therapeutics in a report on Friday, May 16th. They issued a "buy" rating for the company. Guggenheim cut their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Finally, Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1.52.
Get Our Latest Analysis on Adaptimmune Therapeutics
About Adaptimmune Therapeutics
(
Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Stories
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
